| Technology |
|
|
|
| Written by Graham Ruecroft |
| Tuesday, 30 December 2008 20:32 |
|
Equipment | References | SAX | CrystalGEM | Sonocrystallization | DISCUS | Ultrasonic Particle Rounding Controlling and actively manipulating nucleation and subsequent crystal growth behaviour is fundamental to the improvement of crystallization and crystal engineering processes. Prosonix achieve this through the selective application of power ultrasound, via patented particle engineering and crystallization technologies with a Complete Crystallization Control™ philosophy. Ultimately our technologies lead to manufacturing protocols for Advanced Pharmaceutical Ingredients (APIs). The control of crystal particle size of APIs is necessary when the final product performance is reliant upon having well defined and engineered mesoscopic particles, such as in the pharmaceutical and agrochemical industries. The size of the particle and the crystal form of the API can influence behaviour in a biological system, such as rate of dissolution. This is of particular importance given that over 40% of new molecules being developed are poorly water soluble. Please use the link immediately below in order to access a useful paper from the Journal of Process Research and Development, authored by Graham Ruecroft and David Hipkiss: Our technologies include:
Award winning* SAXTM: Solution Atomization and Crystallization by Sonication and related techniques: The unique combination of solution atomization and sonocrystallization for perfect inhalable particles.* Winner: 2006 Royal Society of Chemistry Teamwork in Innovation.
Assisted by:
Award winning* CrystalGEMTM Predictive and highly focussed crystallization screening for small molecule APIs * Winner 2005 CPHI Innovation Award.
Patented equipment as exemplified by ProsonitronTM and SonoLabTM By employing our technology our customers benefit from the control of crystal habit, amorphous & crystal state manipulation, crystallization of the ground-state polymorph form and/or preferential forms, manipulation of crystal size distribution, prevention and reversal of agglomeration and improvements in related product properties such as purity, filtration rate and bulk density. These tangible value-added benefits, arising from the control of physical form, are capitalised at production scale because process repeatability is increased as a result of controlling the nucleation and growth process. Alternatively Prosonix can manufacture your product to cGMP and to your timelines. |
| Last Updated on Wednesday, 05 August 2009 09:51 |